This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. ARVN, ANAB, MRVI, URGN, TYRA, PGEN, ORIC, OMER, VERV, and SAGEShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Arvinas (ARVN), AnaptysBio (ANAB), Maravai LifeSciences (MRVI), UroGen Pharma (URGN), Tyra Biosciences (TYRA), Precigen (PGEN), ORIC Pharmaceuticals (ORIC), Omeros (OMER), Verve Therapeutics (VERV), and Sage Therapeutics (SAGE). These companies are all part of the "medical" sector. Ritter Pharmaceuticals vs. Arvinas AnaptysBio Maravai LifeSciences UroGen Pharma Tyra Biosciences Precigen ORIC Pharmaceuticals Omeros Verve Therapeutics Sage Therapeutics Arvinas (NASDAQ:ARVN) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking. Does the MarketBeat Community favor ARVN or RTTR? Ritter Pharmaceuticals received 107 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 70.23% of users gave Ritter Pharmaceuticals an outperform vote while only 66.55% of users gave Arvinas an outperform vote. CompanyUnderperformOutperformArvinasOutperform Votes19566.55% Underperform Votes9833.45% Ritter PharmaceuticalsOutperform Votes30270.23% Underperform Votes12829.77% Do analysts rate ARVN or RTTR? Arvinas currently has a consensus price target of $35.50, suggesting a potential upside of 394.43%. Given Arvinas' stronger consensus rating and higher probable upside, research analysts clearly believe Arvinas is more favorable than Ritter Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 5 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.67Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in ARVN or RTTR? 95.2% of Arvinas shares are owned by institutional investors. Comparatively, 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. 5.2% of Arvinas shares are owned by insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer ARVN or RTTR? In the previous week, Arvinas had 7 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 7 mentions for Arvinas and 0 mentions for Ritter Pharmaceuticals. Arvinas' average media sentiment score of 0.79 beat Ritter Pharmaceuticals' score of 0.00 indicating that Arvinas is being referred to more favorably in the media. Company Overall Sentiment Arvinas Positive Ritter Pharmaceuticals Neutral Which has higher valuation & earnings, ARVN or RTTR? Ritter Pharmaceuticals has lower revenue, but higher earnings than Arvinas. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M1.87-$198.90M-$2.77-2.59Ritter PharmaceuticalsN/AN/A-$10.13MN/AN/A Which has more risk and volatility, ARVN or RTTR? Arvinas has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, suggesting that its share price is 143% less volatile than the S&P 500. Is ARVN or RTTR more profitable? Ritter Pharmaceuticals has a net margin of 0.00% compared to Arvinas' net margin of -75.51%. Ritter Pharmaceuticals' return on equity of 0.00% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-75.51% -33.75% -16.75% Ritter Pharmaceuticals N/A N/A -162.05% SummaryArvinas beats Ritter Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Remove Ads Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.07M$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-5.457.1123.1218.81Price / SalesN/A205.89369.1988.69Price / CashN/A65.6738.1634.64Price / Book34.906.146.704.18Net Income-$10.13M$142.11M$3.20B$247.10M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.49-4.1%N/A+821.5%$161.07MN/A-5.457ARVNArvinas3.8128 of 5 stars$8.61-1.6%$37.47+335.2%-82.6%$592.13M$263.40M-3.11420Short Interest ↓High Trading VolumeANABAnaptysBio2.8258 of 5 stars$18.71+9.5%$35.11+87.7%-13.7%$573.78M$91.28M-3.08100Buyback AnnouncementHigh Trading VolumeMRVIMaravai LifeSciences4.5409 of 5 stars$2.24-1.3%$8.22+266.9%-74.9%$565.66M$259.19M-1.37610Short Interest ↑High Trading VolumeURGNUroGen Pharma3.2193 of 5 stars$11.90-1.9%$38.20+221.0%-25.1%$548.52M$90.40M-3.78200TYRATyra Biosciences2.0421 of 5 stars$10.65-0.4%$30.50+186.4%-48.3%$538.92MN/A-6.6120Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePGENPrecigen3.4287 of 5 stars$1.82+0.6%$7.00+284.6%+0.3%$535.16M$3.93M-3.31190Gap UpORICORIC Pharmaceuticals4.1999 of 5 stars$7.37+4.8%$18.86+155.9%-57.2%$523.47MN/A-4.0580Gap DownOMEROmeros3.6141 of 5 stars$9.02-0.9%$22.50+149.4%+148.0%$522.71MN/A-3.90210Analyst ForecastNews CoverageVERVVerve Therapeutics1.7113 of 5 stars$5.78+4.1%$25.50+341.2%-67.6%$513.24M$32.33M-2.35110News CoverageSAGESage Therapeutics3.4293 of 5 stars$8.21+1.4%$8.81+7.3%-56.1%$504.76M$41.24M-1.25690 Remove Ads Related Companies and Tools Related Companies Arvinas Competitors AnaptysBio Competitors Maravai LifeSciences Competitors UroGen Pharma Competitors Tyra Biosciences Competitors Precigen Competitors ORIC Pharmaceuticals Competitors Omeros Competitors Verve Therapeutics Competitors Sage Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RTTR Stock Free RTTR Stock Alerts